Stock Research: Evolus

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Evolus

NasdaqGM:EOLS US30052C1071
16
  • Value
    13
  • Growth
    35
  • Safety
    Safety
    63
  • Combined
    13
  • Sentiment
    42
  • 360° View
    360° View
    16
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Evolus, Inc. is a performance beauty company focused on cash-pay aesthetic medical products. It operates in the medical aesthetics industry with product categories including injectable neurotoxins (Jeuveau) and injectable hyaluronic acid gels (Evolysse). Jeuveau is available in the United States, Canada, and certain European markets, while Evolysse is available in the United States and Europe. In the last fiscal year, the company had a market cap of $599 millions, profits of $182 millions, revenue of $266 millions, and 332 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 16 (better than 16% compared with alternatives), overall professional sentiment and financial characteristics for the stock Evolus are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Evolus. Only the consolidated Value Rank has an attractive rank of 63, which means that the share price of Evolus is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 63% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 35, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 13, meaning the company has a riskier financing structure than 87% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 58% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 42. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 4 65 43
Growth
35 81 87 97
Safety
Safety
13 9 13 6
Sentiment
42 90 54 76
360° View
360° View
16 33 59 64
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
93 95 54 31
Opinions Change
50 75 31 75
Pro Holdings
n/a 18 24 82
Market Pulse
37 89 89 40
Sentiment
42 90 54 76
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
63 4 65 43
Growth
35 81 87 97
Safety Safety
13 9 13 6
Combined
13 4 61 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
9 4 100 16
Price vs. Earnings (P/E)
81 41 40 62
Price vs. Book (P/B)
100 1 100 28
Dividend Yield
1 1 1 1
Value
63 4 65 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
81 87 89 79
Profit Growth
10 76 63 62
Capital Growth
69 45 43 83
Stock Returns
3 61 85 73
Growth
35 81 87 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
7 3 11 3
Refinancing
53 32 29 49
Liquidity
31 27 27 20
Safety Safety
13 9 13 6

Similar Stocks

Discover high‑ranked alternatives to Evolus and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Intuit

NasdaqGS:INTU
Country: USA
Industry: Application Software
Size: X-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.